Lianbio (LIAN) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lianbio  (NASDAQ: LIAN)

Lianbio's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Lianbio in the third quarter 2023?
Lianbio recorded a cumulative net loss of $-20 million during 12 months ending in the third quarter 2023, resulting in a negative return on equity (ROE) of -7.36%.

Within the Major Pharmaceutical Preparations industry 63 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2023 from 2208 to 2218.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change -22.99 % -21.67 % -24.77 % -24.19 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -20 -19 -19 -18 -21
Return On Equity (TTM) -7.36 % -6.7 % -6.24 % -5.67 % -6.13 %
LIAN's Total Ranking # 2218 # 2208 # 1825 # 2311 # 0
Equity (TTM) in Millions 236 256 274 294 307
Seq. Equity Change -7.59 % -6.9 % -6.55 % -4.22 % -6.01 %
Seq. Net Income Change - - - - -

Back to LIAN Management Effectiveness >> LIAN's 5 Years Annual ROE >> Compare LIAN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 64
Sector # 187
Overall # 2218

Return On Equity Statistics
High Average Low
0.1 %
-0.08 %
-0.33 %
(Dec 31 2022)  





LIAN Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021


Total Equity in Millions 294 387 0 0 0
Y / Y Equity Change -24.19 % - - - -
Net Income in Millions 0 -1 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity 0.11 % -0.13 % - - -

Back to LIAN Management Effectiveness >> LIAN's 5 Years Annual ROE >> Compare LIAN ROE to its Competitors




Annual Roe Comment
In 2022 ROE improved to 0.11 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LIAN's' Return on Equity at Yahoo Finance
LIAN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LIAN's Competitors
Subscribers only: Roe for Lianbio's Suppliers
Subscribers only: Return On Equity for LIAN's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE

Date modified: 2026-09-08T15:11:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.